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Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men.
in contrast to other nonsteroidal anti-inflammatory drugs (NSAIDs),
sulindac has been reported to inhibit systemic prostaglandins (PGs)
while not affecting renal PGs. We studied 11 normal volunteers who
received placebo, ibuprofen, naproxen, or sulindac in a randomized,
double-blind fashion. After control periods assessing the effect of the
NSAIDs alone, 40 mg of furosemide were administered. Overall, each
of the drugs appeared similar. Renal function, plasma renin activity
(PRA) and urinary PGs were not affected during control collections,
while all three NSATDs decreased thromboxane B2 (TxB2). After
furosemide, all NSAIDs decreased fractional excretions of Na and
Cl, PRA, and TxB2 by equivalent degrees (P < 0.05). Sulindac and
ibuprofen decreased urinary PGE2 (P < 0.05) while naproxen had no
effect. None of these drugs affected the excretion of furosemide, but all
decreased the pharmacodynamics of response to furosemide. In conclu-
sion, the effects of these NSAIDs depended on the conditions of the
study. In the basal state there were no renal effects but all decreased the
renal response to furosemide.
Effets de l'ibuprofène, du naproxène, et du sulindac sur les
prostaglandines che les hommes. A l'opposé d'autres médicaments
anti-inflammatoires non stéroidiens (NSAIDs), il a été rapporté que Ic
sulindac inhibe les prostaglandines systémiques (PUs), mais n'affecte
pas les PUs rénales. Nous avons étudié II volontaires sains qui ant recu
du placebo, de l'ibuprofène, du naproxène, ou du sulindac d'une
maniêre randomisée, en double insu. Apres les périodes contrôles
étudiant l'effet des NSAIDs seuls, 40 mg de furosémide ont été
administrés. Globalenient, chacun des mCdicaments apparaissait sembl-
able. La fonction rénale, l'activité rénine plasmatique (PRA) et les PGs
urinaires n'étaient pas modiflées pendant les collections contrôles, alors
que les trois NSAIDs diminuaient le thromboxane B2 (TxB2). AprCs
furosémide, tous les NSAIDs diminuaient les excretions fractionnelles
de Na et C1, PRA et TxB2 de facon equivalente (P < 0,05). Le
sulindac et l'ibuprofène diminuaient la PGE2 urinaire (P < 0,05), alors
que Ic naproxène était sans effet. Aucun de ces médicaments n'affectait
l'excrétion du furosémide. mais tous diminualent Ia pharniacodyna-
mique de Ia réponse au furosémide. En conclusion, les effets de ces
NSAIDs dependaient des conditions de l'étude. A l'état basal, il ny
avait pas d'effet renal, mais tous diminuaient La rCponse rénale au
furosémide.
Nonsteroidal anti-inflammatory drugs are well known to
decrease renal function [1—15]. The most common type of acute
renal failure caused by these drugs appears to occur by an
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ischemic mechanism and is most frequently exhibited in dis-
eases in which the local synthesis of vasodilatory prosta-
glandins (PUs) is a critical determinant of renal perfusion.
Animal models of congestive heart failure, cirrhosis, sodium
depletion, and hemorrhage demonstrate increased activity of
the sympathetic nervous and renin-angiotensin systems. The
resultant increase in vasoconstricting autocoids is matched by
the synthesis of PGs, thereby maintaining renal perfusion.
Inhibition of renal PG synthesis results in unopposed renal
vasoconstriction which may lead to acute ischemic renal failure
[16—191. In humans, sodium-deprived normal subjects [14, 15]
and patients with heart failure, cirrhosis, and intrinsic renal
disease appear to be most susceptible to this effect [1—13, 201,
and caution must be exercised when administering NSAIDs in
these clinical settings. Recently, sulindac has been reported to
differ from other NSAIDs by sparing renal but inhibiting
systemic PGs as reflected by the lack of effect on urinary
prostaglandin E2 (PGE2) excretion and on other putative end
points of renal PG synthesis such as renin release and response
to furosemide while inhibiting systemic PGs as reflected by the
decreased production of thromboxane by platelets [20—22].
Other preliminary studies report disparate findings [23—26]. A
differential effect of sulindac would considerably improve its
therapeutic index relative to other NSAIDs. We felt that any
putative advantage required closer scrutiny, for heretofore
published studies have been conflicting [20—261. Consequently,
we performed the current randomized, double-blind, placebo-
controlled study in normal subjects. Our data do not support an
overall renal sparing effect of sulindac.
Methods
Study protocol
We studied eleven healthy men, 23 to 34 years old, and asked
them to refrain from sexual activity throughout the duration of
the study to avoid contamination of urine samples with seminal
fluid PGs [27]. Prior to the study, the subjects were asked to
provide a complete medical history, and they were given
physical examinations including a screening of blood chemis-
tries, blood counts, and urinalysis to verify their lack of disease.
The study was of double-blind, four-way crossover, balanced
block design with random assignment to four treatments: pla-
cebo, ibuprofen, naproxen, and sulindac. All subjects com-
pleted all phases of the study. Each treatment period consisted
of 5 days during which the subjects ingested a metabolic diet of
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Placebo Placebo Placebo
Naproxen, 375 mg Placebo Naproxen, 375 mg
Sulindac, 200 mg Placebo Sulindac. 200 mg
Ibuprofen, 600 mg Ibuprofen, 600 mg Ibuprofen, 600 mg
10 mEq Na/day. All meals were eaten on the General Clinical
Research Center (GCRC). Urinary electrolytes were measured
on a 24-hr urine sample collected from 8 P.M. of day 3 to 8 P.M.
of day 4 to determine compliance with the diet. Urinary sodium
excretion in this sample was 17 4, 14 4, 17 4, and 17
4 mEq/24 hr before placebo, ibuprofen, naproxen, and sulindac,
respectively. Subjects were asked to withhold food and fluids
after midnight of day 4, for the clearance study conducted on
day 5. A drug, randomly assigned, was ingested at —12, —6,
and — 1 hr in the order shown in Table 1. We felt this regimen
would approximate "normal" dosing of these drugs albeit
acute. Though argument could be made for the need for more
chronic dosing, it is important to note that the ischemic renal
insult observed with NSAIDs occurs quickly. Elevations of
serum creatinine occur within 24 hr of exposure to the NSAID
indicating that the deleterious effect probably occurs with initial
exposure to the drug [281. Treatment periods were separated by
at least 14 days. At time 0, the subjects received priming doses
of inulin and para-aminohippurate (PAH) through an intra-
venous catheter placed in one forearm followed by a main-
tenance infusion throughout the duration of the clearance study
calculated to maintain serum concentrations of inulin and PAH
of 25 and 1.5 mg%, respectively. These markers of renal
hemodynamics were administered by an infusion pump
(Harvard) at a rate of approximately 1 ml/min. During a 45-mm
equilibration period, the subjects drank a water load of 5 mI/kg
of body wt to assure sufficient urinary output so spontaneously
voided urine samples could be collected. At the end of the
45-mm equilibration period, subjects voided and three 20-mm
collection periods ensued, during which midpoint blood sam-
ples were obtained for measurement of electrolytes, creatinine,
inulin, PAH, plasma renin activity (PRA), and osmolality. At
the midpoint of the third collection period, blood samples were
also obtained for measurement of serum and plasma throm-
boxane (TxB2). The latter samples were collected in glass tubes
containing 100 U/mI of heparin and 1 g/ml of indomethacin.
After the three baseline collection periods, 40 mg of furosemide
were administered as an intravenous bolus over 2 to 3 mm after
which six 20-mm collection periods ensued. At the midpoint of
the second collection period, blood samples were again col-
lected to measure TxB2. For the duration of the study, urinary
losses were replaced intravenously with 5%dextrose and water
including 1 mI/mm for insensible water loss. All urine samples
were measured for volume, creatinine, electrolytes, P04,
inulin, PAH, PGE2, 6 keto-PGF1 osmolality, and furosemide,
the latter where appropriate. On the 2 days following the period
of observation, blood urea nitrogen (BUN), serum creatinine,
and urinalysis were obtained as a safety follow-up. No adverse
effects occurred.
Assays
Sodium and potassium were measured with ion-specific elec-
trodes, chloride by potentiometric titration, and creatinine by
the Jaffe reaction with an autoanalyzer (Beckman Astra 8,
Beckman Instruments, Inc., Fullerton, California, USA); inulin
and PAH were measured with an autoanalyzer (Technicon
Instruments Corporation, Tarrytown, New York, USA)
[29—3 1]; osmolality was measured by freezing point depression
with a micro-osmometer (Precision Systems); phosphate as
total phosphorus by the method of Fiske and Subbarow [321;
and furosemide by high performance liquid chromatography as
previously described [33, 341. Plasma renin activity was mea-
sured by radioimmunoassay using the antibody trapping proce-
dure of Poulson and Jorgensen [351. Urinary PGE2 and 6
keto-PGF1 and serum and plasma TxB2 were measured by
radioimmunoassay by the method of Dray, Charbonnel, and
Maclouf [361 as modified by Campbell et al [37, 38]. Briefly, 2 ml
of urine or 4 ml of plasma were acidified to pH 3.0 with glacial
acetic acid and passed through a 6 ml Baker C18 extraction
column that had been previously washed with ethanol and
water [39]. The column was washed successively with 5 ml of
15% ethanol in water and toluene and the PGs were eluted with
2 ml of ethyl acetate. This eluate was evaporated to dryness
under a stream of nitrogen and further purified by silicic acid
chromatography [39]. The PG containing fraction was assayed
by radioimmunoassay. One-tenth milliliter of the reconstituted
fraction was mixed with 0.1 ml of 3H-PG and 0.1 ml of the
diluted antiserum. After incubation overnight at 4°C, the bound
and free PGs were separated with dextran-coated charcoal and
the bound counts were estimated by liquid scintillation spec-
trometry. The results were corrected for recovery and ex-
pressed as nanograms of picograms per milliliter. With each
assay a water blank is assessed. To avoid any artifact of
increased urinary volumes, if a water blank is elevated, the
assay is discarded and repeated.
Data analysis
Effects of the different NSAIDs were assessed during both
the control periods and after furosemide. In the former, values
for each of the three control collections in an individual subject
were averaged; in the latter, values encompassing the peak
response to furosemide (invariably the first three collections)
were averaged. Global renal handling of water was assessed as
urinary flow rate (V); global renal handling of solute as sodium
and chloride excretion rates (Na and Cl) and as their fractional
excretions (FENa and FEc1); glomerular filtration rate (GFR) as
clearances of creatinine and of inulin (Cc. and C1) [40]; and
renal plasma flow (RPF) as clearance of PAH (CPAH) [28, 29].
Since the accuracy of this measure depends on the secretion of
PAH into urine, the presence of furosemide and/or NSAIDs
could obviate using CPAH as a measure of RPF. Though Bartha
and Hably [411 have shown that indomethacin does not affect
secretion of PAH, similar data do not exist for the drugs used in
this study. Consequently, these data should he interpreted with
these caveats in mind. Phosphate excretion rate (P04) was used
as a nonspecific index of proximal tubular function [42, 43].
The pharmacodynamics of fuorsemide were assessed as
"dose-response" curves by plotting the logarithm of urinary
furosemide excretion rate (sg/min) versus Na excretion rate
Table 1. Assignment of drug given to subjects on day 5 of the study
Time drug ingested
—12 hr
—6hr —1 hr
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Table 2. Effect of NSAIDs on renal function (mean sEM)
Placebo Ibuprofen Naproxen Sulindac
V, mI/mm 2.97 0.70 2.97 0.61 3.28 0.80 3.24 0.73
Na, mEqimin 0.022 0.005 0.017 0.003 0.17 0.004 0.021 0.004
FENa, % 0.16 0.03 0.11 0.02 0.13 0.03 0.18 0.03
Cl, mEqlmin 0.014 0.003 0.007 o.oola 0.013 0.003 0.014 0.002
FE1, % 0.14 0.03 0.07 0.Ola 0.14 0.03 0.15 0.02
P04, mg/mm 0.52 0.08 0.42 0.05 0.38 0.06 0.41 0.04
C1,, mI/mm 105 6 111 9 106 5 98 10
Car, mI/mm 155 7 164 12 157 7 153 8
CPAH, mI/mm 635 46 657 56 655 50 674 69
Abbreviations: V, urinary flow rate; a and a, global renal handling of solute as sodium and chloride excretion rates; FENa and FEc1, fractional
excretions of sodium and chloride; P04, phosphate excretion rate; C1,, clearance of inulin; Car, clearance of creatinine; CPAH, clearance of PAH.
a The effects of ibuprofen were significantly more than the placebo.
Table 3. Effect of NSAIDs on plasma renin activity, urinary prostaglandins, and circulating thromboxane (mean sEM)
Placebo Ibuprofen Naproxen Sulindac
PRA ng Al/mI/mm 2.7 0.3 2.7 0.2 2.5 0.2 2.6 0.1
Urinary PGE2 ng/min 0.21 0.05 0.17 0.02 0.16 0,03 0.14 0.03
Urinary 6 keto-PGF1, ng/min 0.24 0.09 0.14 0.02 0.20 0.05 0.12 0.02
Serum TxB2 ng/mI 0.94 0.26 0.04 o.ola 0.06 0.03a 0.43 010a,b
Plasma TxB2 ng/ml 0.049 0.012 0.015 0.008a 0.010 0.002a 0.016 o.oo4
a The effects were significantly more than the placebo.
b The effects were significantly less than ibuprofen or naproxen.
(mEq/min) for all six collection periods. These sigmoid-shaped
curves were analyzed using the ALLFIT computer program to
fit the curve to a standard format [44]:
Y= a-d
X b1+ (—)
c
The model used is the four parameter logistic equation where Y
and X are response and dose, respectively, and a, b, c, and d
are the four derived parameters where a is the response at zero
dose, b is the "slope factor," c is the dose causing half maximal
response (ED50), and d is the response at infinite dose or
maximal response. Response at zero dose, a, was fixed as the
sodium excretion rate during the appropriate control period.
Differences among groups were tested using analysis of
variance. We used Bartlett's test to assess the equality of
variances. If they were equal, we used a Newman-Keuls
multiple comparison; if variances were not equal, we used a
Welch's approximation of nonparametric analysis. Values are
expressed as mean SEM.
Results
Effect of NSAIDs alone
Neither ibuprofen, naproxen, nor sulindac appreciably af-
fected renal function during the control period, except the
decrease in chloride excretion caused by ibuprofen (P < 0.03;
Table 2). Similarly, none of these NSAIDs significantly affected
PRA or urinary excretion of PGE2 or 6 keto-PGF1,,, though the
PGs tended to decline (Table 3). In contrast, TxB2 was de-
creased by all three agents whether assessed as plasma concen-
tration or as production in serum (Table 3). Interestingly, with
the latter assay, though sulindac significantly decreased TxB2
compared to the placebo (P < 0.025), this effect was less than
that of either ibuprofen (P < 0.025) or naproxen (P < 0.05).
Each of the latter markedly decreased TxB2 compared to the
placebo (P < 0.001). This difference among agents was not
apparent with measures of plasma TxB2 concentration, where
each NSAID had similar quantitative effects (P < 0.01). Over-
all, then, during the control periods, each of these drugs
suppressed systemic PGs as assessed by effects on TxB2 while
all had negligible effects on renal PGs or function.
Effect of NSAIDs on response to furosemide
In contrast to the control collections, each of the NSAIDs
decreased response to furosemide (Table 4). Naproxen tended
to have the least effect and ibuprofen the greatest, although
differences among drugs were not significant. Neither GFR nor
RPF was affected. Phosphate excretion tended to decrease but
not significantly.
Each of these drugs could potentially affect response to
furosemide by inhibiting its active secretion to its intraluminal
site of action. Neither total amounts of furosemide nor the time
course of its delivery into urine were affected by the NSAIDs
(Fig. 1). Consequently, the effect on the response to furosemide
is not a pharmacokinetic interaction, but instead is pharmaco-
dynamic in nature, causing a shift in the relationship between
amounts of furosemide at its urinary site of action and natriu-
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Table 4. Effect of NSAIDs on the renal effects of furosemide (mean SaM)
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16.8 0.9
2.61 0.09
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retic response (Fig. 2). Table 5 presents derived parameters of
these "dose' '-response curves. Basal sodium excretion, the
slope factor of the dose-response curve, and the dose causing
half-maximal response (ED50) were not affected by any of
the NSAIDs. In contrast, all significantly decreased maximal
response (P < 0.005) with ibuprofen (P < 0.001) and sulindac
(P < 0.025), being significantly more potent than naproxen and
ibuprofen being more potent than sulindac (P < 0.025). This
pattern of effect is similar to that which we have previously
described with indomethacin [34].
All three agents blunted fuorsemide-stimulated increases in
PRA (P < 0.025) whereas only ibuprofen (P < 0.01) and
sulindac (P < 0.03) suppressed urinary excretion of PGE2
(Table 6). Effects on urinary 6 keto-PGF1,,, were qualitatively
similar to those on PGE2 although differences were not sig-
nificant (Table 6). Similar to effects of these drugs on solute
excretion, ibuprofen appeared to be most potent and naproxen
the least. Effects of the NSAIDs on TxB2 were similar to those
during the control collections. Although ibuprofen, naproxen,
and sulindac decreased serum production of TxB2 compared to
the placebo (P < 0.001, P < 0.001, P < 0.025), the effects of
ibuprofen (P < 0.025) and naproxen (P < 0.05) were greater
than that of sulindac. A similar qualitative effect was seen when
assessing plasma TxB2 concentration where both ibuprofen and
naproxen caused tenfold decreases (P < 0.001) whereas the
decrease with sulindac escaped significance (P = 0.078).
Discussion
One clinical problem with the use of NSAIDs is the nonselec-
tive nature of their inhibition of PG synthesis. Consequently,
potential salutory effects of inhibiting PGs in one organ system
can be offset by adverse effects elsewhere. This drawback has
been particularly evident with respect to the acute renal failure
that has occurred with these agents [1—151. Recent data have
indicated that sulindac might differ from other NSAIDs by
sparing renal PGs while inhibiting synthesis of those elsewhere
[20—22]. Because the mechanism of acute renal failure with
NSAIDs appears in most cases to occur by inhibition of
vasodilatory renal PGs allowing vasoconstriction mediated by
Placebo Ibuprofen Naproxen Sulindac
V, mi/mm
Na, rnEq/min
FENa, %
Cl, mEqlmmn
FE1, %
P04, mg/mm
C1,,, mi/mm
Ccr, rn//rn in
CPAH, mi/mm
Abbreviations are the same as those used for Table 2.
a The effects were significantly more than the placebo.
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Fig. 2. "Dose" response curves tofurosemide relating the logarithm of
Time, mm urinary furosemide excretion rate (gImin) to response quantj/ied as
Fig. 1. Time course of delivery of furosemide into urine with the total sodium excretion rate (mEqimmn).
amount of diuretic excreted quantified in the figure.
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Table 5. Derived parameters of furosemide dose-response curves (mean SEM)
Maximal response, tnEqlmin 2.43 0.20
a The effects were significantly more than the placebo.
b The effects were significantly less than ibuprofen or sulindac.
The effects were significantly more than sulindac.
Ibuprofen Naproxen
Table 6. Effect of NSAIDs on plasma renin activity, urinary prostaglandins, and circulating thromboxane after furosemide (mean SEM)
PRA, ng Al/mi/mm
Urinary PGE2, nglmmn
Urinary 6 keto-PGF1, nglmin
Serum TxB2, ng/mi
Plasma TxB2, ng/m!
Placebo
5.5 0.6
1.28 + 0.20
0.98 0.30
0.88 0.19
0.078 0.029
Ibuprofen
34
0.66 o.06
0.46 0.04
0.06 0.03u
0.007 ÷ 0.00l
Naproxen
3.6 0.4
1.21 0.29
1.19 0.29
0.03 + 0.02
0.008 0.002"
Sulindac
3.6 0.5'
0.88 0.13
0.66 0.12
0.38 0•09a.b
0.025 0006b
the sympathetic nervous system and angiotensin to be un-
opposed [16—19], a renal sparing NSAID would offer consider-
able advantages. It would be expected to cause less, if any,
nephrotoxicity and might thereby be safer than other NSAIDs
in patients at risk for this type of ischemic acute renal failure.
Unfortunately, recent preliminary reports have not substanti-
ated a renal sparing effect of sulindac 123—261. Consequently,
we felt the need for a more rigorous study.
Certain patient groups are at a higher risk for the adverse
renal effects of NSAIDs including those with congestive heart
failure, cirrhosis with ascites, and probably various forms of
intrinsic renal disease [1—13, 20]. In these settings, the main-
tenance of renal perfusion appears to depend on local synthesis
of PGs. One might argue that our study should have been
conducted in a susceptible patient group. However, we felt that
such patient groups most likely encompass a wide range of
pathophysiologies, even within one diagnostic category.
Hence, we sought a model in which potential variables could be
more rigidly controlled, realizing that our findings might not
extrapolate directly to clinical settings. On the other hand, they
would serve as a valid starting point. Consequently, we chose
to study a model in normal subjects which amplifies the role of
renal PGs, thereby better enabling us to detect renal effects of
NSAIDs or a lack thereof. Muther and Bennett [141 and
Muther, Potter, and Bennett [151 showed that GFR decreased in
normal subjects who had equilibrated on a 10 mEq/day sodium
diet when they were given sufficient aspirin to inhibit renal PUs,
These data implied that the sodium-deprived state in normal
subjects in some respects mimicked clinical conditions such as
heart failure in which the local synthesis of vasodilatory PGs is
required to maintain renal perfusion [19].
In the current study, none of the NSAIDs appreciably
affected renal function or urinary PGs (Tables 2 and 3). On one
hand, these data do not support a difference between sulindac
and either ibuprofen or naproxen, but on the other, they differ
from the findings cited above of Muther and Bennett [14] and
Muther, Potter, and Bennett [15]. Two factors probably ac-
count for this difference: (1) Though the amounts of NSAIDs
we used were "average" doses used clinically, they were
insufficient to inhibit renal PGs in this model and (2) our
subjects did not appear to have been as sodium-depleted as
were those of the Muther and Bennett study, as reflected by a
PRA in our subjects of 2.7 compared to 6.4 in theirs and by
values for urinary PGE7 excretion in our subjects similar to
those in sodium-replete patients.
Despite a lack of effect on renal PGs, however, these doses of
NSAIDs were sufficient to inhibit TxB2 whether measured as
production in an incubate of serum or as plasma concentration
(Table 3). Interestingly, this observation implies that synthesis
of thromboxane is more sensitive to NSAIDs than is renal PG
synthesis. When assessed as serum production of TxB2, but not
as plasma concentration, sulindac had less effect than ibuprofen
or naproxen. We cannot explain this difference or speculate as
to its clinical implications.
Do these data imply that ibuprofen and naproxen might also
be renal sparing? Strictly speaking, in this model, at these
doses, both ibuprofen and naproxen spared renal PGs. How-
ever, we think these data are more appropriately interpreted to
imply that different NSAIDs have different potencies and that
different sites of PG synthesis (for example, renal interstitium
versus vascular endothelium versus platelet) probably have
differing sensitivites to PG inhibition. Large doses of any
NSAID will probably inhibit all PGs whereas differences among
drugs will become manifest at lower doses and in different
Basal response, mEq/min
Slope factor, mEq/p.g
ED50, j.g/min
Placebo
0.022
3.34 1.14
84.2 + 9.7
0.017
3.45 1.91
80.6 12.9
1.60 0.20c
Sulindac
0.017
3.10 -'- 1.24
90.7 12.7
2.08 0,21a,h
0.021
3.31 1.50
94.9 15.2
1.84 0.22"
a The effects were significantly more than the placebo.
b The effects were significantly less than ibuprofen or naproxen.
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conditions or models as a function of the PG source being
monitored.
Administration of furosemide stimulates renal PGs and, in
fact, Nies et al [451 have shown that the hemodynamic compo-
nent of response to furosemide is mediated by PGs. We felt it
might be reasonable to presume that this PG-mediated vascular
effect is analagous to the PG-mediated vasodilation in patients
susceptible to the adverse renal effects of NSAIDs. Conse-
quently, we used furosemide as an additional test of effects of
the various NSAIDs on renal function. Ibuprofen, naproxen,
and sulindac all had similar effects whether assessing renal
function (Tables 4 and 6) or the pharmacodynamics of response
to furosemide (Fig. 2 and Table 5). In the doses used in this
study, ibuprofen seemed to be most potent and naproxen the
least in terms of effects on the kidney. In contrast, just as in the
control periods, in terms of effects on TxB2, ibuprofen and
naproxen were of comparable potency while sulindac was less
so. These data again demonstrate differences in sensitivity of
thromboxane as opposed to renal PG synthesis.
We attempted to use the clearance of PAH as an indirect
measure of renal blood flow. Although furosemide and other
loop diuretics have clearly been shown to increase renal blood
flow when using electromagnetic flow probes, PAH clearance
has proven to be a less reliable marker. In fact, in most studies
in humans in which high basal urinary flow rates are attained
(water loading) which minimizes any "wash out" phenomenon
associated with acute administration of the diuretic, PAH
clearance has not increased with furosemide administration [46,
47]. Furosemide can compete for tubular secretion of PAH,
perhaps accounting for these observations. Although averaging
three collections after furosemide could conceivably have ob-
scured a transient increase in clearance of PAH, analysis of the
data showed no such brief effect.
Presumably, prostacyclin (PGI2) mediates the vascular ef-
fects of furosemide [48]. Consequently, patterns of effects on
urinary excretion of 6 keto-PGF1 might be more informative
than those on PGE2. Unfortunately, however, it is not known
whether changes in urinary 6 keto-PGF1 reflect renal or
systemic synthesis of PGI2 (or more likely, a combination) [49,
50]. Consequently, we are reluctant to interpret the patterns of
6 keto-PGF1a excretion observed in this study other than their
qualitative similarity to those of PGE2, thereby confirming a
potency heirarchy of these drugs on PGI2 similar to that on
PGE2.
Our data do not support an overall renal sparing effect of
sulindac, which are findings which differ from the original and a
subsequent report of Ciabattoni et al [20, 21]. In their first
report [21], these authors performed several different protocols.
In one study, they assessed the effects of 300 mg/day of sulindac
on basal 24 hr urinary PG excretion and on serum TxB2
production in three healthy women. In one of these subjects,
after sulindac had been discontinued, the patient was re-
evaluated on 150 mg/day of indomethacin. At these doses,
sulindac did not affect urinary PGs or PRA while in the patient
who received indomethacin both decreased. A similar pattern
was observed in one patient with Bartter syndrome. The last
protocol involved measurement of PRA and serum TxB2 pro-
duction in four men administered furosemide with and without
pretreatment with 800 mg of sulindac. Sulindac had no effect on
either basal or furosemide-stimulated PRA but markedley sup-
pressed TxB2. No comparison was made with other NSAIDs
and effects on renal function were not reported.
Recently, this same group studied 20 women with chronic
glomerular diseases comparing 1 week of treatment with 1.2
g/day of ibuprofen to 400 mg/day sulindac [20]. Sulindac did not
affect urinary excretion of PGE2 or 6 keto-PGF1a or cause renal
function to deteriorate while serum TxB2 decreased 85%. In
contrast, ibuprofen caused approximately 80% decreases in
both urinary PGs, a 30% decrease in Ccr, and a 35% decrease in
CPAH.
A preliminary report from another group support
Ciabottoni's findings. Twelve cirrhotic patients with ascites
received acute administration of 150 mg of sulindac or 50 mg of
indomethacin [26]. The latter significantly decreased basal
sodium and volume excretion and Ccr fell from 99 19 to 45
11 mI/mm. Sulindac had no effect.
Lastly, a recent case report described three patients who
suffered acute renal failure with ibuprofen or naproxen but were
able to tolerate sulindac [231.
On the other hand, the current study and other reports offer
conflicting data [23—26]. In the same study in cirrhotics cited
above [26], although sulindac spared basal renal function, its
effects to inhibit response to furosemide were identical to those
of indomethacin. In three additional studies, sulindac has been
compared to 5 to 6 days of treatment with indomethacin [23],
naproxen [24], or ibuprofen [25] in normal subjects. In these
studies, sulindac had no effect on basal renal function but
inhibited response to furosemide in a similar qualitative but
different quantitative fashion than the other NSAIDs.
Lastly, it is important to note that acute renal failure has also
occurred with large doses of sulindac in an elderly patient [13].
Also, in the original description of aspirin causing decrements
in renal function in patients with lupus nephritis, the two signal
patients were successfully switched to 2.0 and 2.4 g/day of
ibuprofen [11].
Our bias is that all available NSAIDs can inhibit renal PGs
and can cause acute ischemic renal failure if given in sufficient
doses. The renal sparing effect of sulindac may simply reflect
that common clinical doses are at the "low end" of the
dose-response curve in terms of inhibition of renal PGs while
relatively higher doses of other NSAIDs are used. In addition,
different pathologies and models probably have different sus-
ceptibilities to inhibit PG synthesis. Our data demonstrate
differences in susceptibility of different PG systems within a
normal individual. Indeed, in the doses we used, the potency
heirarchy for renal effects of ibuprofen > sulindac > naproxen
differed from the heirarchy for effects on TxB2 of ibuprofen
equal naproxen > sulindac. One would predict similar, if not
greater, differences among patients. Although an overall renal-
sparing NSAID would be a welcome advantage to our thera-
peutic armamentarium, we do not feel that sulindac totally
fulfills this criterion, and we urge that cautions be exercised in
its use similar to those with other NSAIDs. Our findings should
be tested in other suscpetible patient groups because the
findings of Ciabottoni et al [20] in patients with glomerular
diseases may not extrapolate to other clinical settings. In
addition, when using NSAIDs as a research tool to inhibit PGs,
one cannot make a priori assumptions as to which PGs will be
inhibited and to what degree.
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